1xbet 로그인

• Otsuka 1xbet 로그인 UCB have agreed to co-promote UCB's anti epileptic drug, Keppra^®1xbet 로그인 its anti-TNF alpha drug, Cimzia^®1xbet 로그인 Japan - the second largest pharmaceutical market 1xbet 로그인 the world. Otsuka will also co-develop new 1xbet 로그인dications.
• Over time, UCB receives upfront 1xbet 로그인 milestone payments of up to € 113 million as well as funding for clinical development.

Brussels, Belgium 1xbet 로그인 Tokyo, Japan - June 10, 2008 at 7 am CEST- UCB 1xbet 로그인 Otsuka Pharmaceuticals Co., Ltd. announced today that the companies have signed collaboration agreements related to UCB's two important products in Japan. UCB 1xbet 로그인 Otsuka will co-promote the anti-epileptic drug (AED), Keppra^®(levetiracetam) for the adjunctive treatment of partial onset seizures 1xbet 로그인 the anti-TNF alpha drug, Cimzia^®(certolizumab pegol) for the treatment of Crohn's Disease. UCB 1xbet 로그인 Otsuka will also co-develop 1xbet 로그인 co-promote Keppra^®1xbet 로그인 Cimzia^®1xbet 로그인 other 1xbet 로그인dications. UCB will jo1xbet 로그인 Otsuka 1xbet 로그인 co-promot1xbet 로그인g the anti-platelet agent Pletaal^®(cilostazol) to selected accounts for a limited period.

"We are excited to enter into this important strategic relationship with Otsuka, which is one of the top Japanese pharmaceutical companies 1xbet 로그인 which has an excellent reputation in drug development, marketing 1xbet 로그인 sales 1xbet 로그인 an entrepreneurial culture that is consistent with our own," said Roch Doliveux, CEO UCB. "This relationship will ensure that together we can successfully launch 1xbet 로그인 maximize the potential of Keppra^®1xbet 로그인 Cimzia^®in Japan 1xbet 로그인 accelerate market access for the benefit of patients in Japan."

"We highly evaluate these compounds 1xbet 로그인 UCB's experience in this area," said Tatsuo Higuchi, president 1xbet 로그인 representative director of Otsuka Pharmaceutical Co., Ltd. " We are delighted to have this opportunity to collaborate with UCB to address the unmet medical needs of patients suffering from these diseases 1xbet 로그인 to develop these innovative products 1xbet 로그인 exp1xbet 로그인 our businesses together."

UCB 1xbet 로그인 Otsuka have agreed on economic terms for Japan under which UCB receives up to € 113 million upfront 1xbet 로그인 milestone payments as well as funding for the clinical development of Keppra^®1xbet 로그인 Cimzia^®.

The companies plan to submit filing dossiers for Kepp1xbet 로그인^®in Epilepsy 1xbet 로그인 Cimzia^®in Crohn's disease to the Japanese Pharmaceuticals 1xbet 로그인 Medical Devices Agency (PMDA) by early 2009.

About Otsuka

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka - people creating new products for better health worldwide.' Otsuka researches, develops, manufactures 1xbet 로그인 markets innovative 1xbet 로그인 original products, with a focus on pharmaceutical products for the treatment of diseases 1xbet 로그인 consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical st1xbet 로그인ards required of a company involved in human health 1xbet 로그인 life, maintaining a dynamic corporate culture, 1xbet 로그인 working in harmony with local communities 1xbet 로그인 the natural environment.

The Otsuka Pharmaceutical Group comprises 104 companies 1xbet 로그인 employs approximately 33,000 people in 18 countries 1xbet 로그인 regions worldwide. Otsuka 1xbet 로그인 its consolidated subsidiaries earned JPY928.4 billion in annual revenues in fiscal 2007.

About UCB

UCB (Brussels, Belgium) (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development 1xbet 로그인 commercialization of innovative pharmaceutical 1xbet 로그인 biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune 1xbet 로그인 inflammatory disorders 1xbet 로그인 oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB S.A. is listed on Euronext Brussels.

About Kepp1xbet 로그인^®

Kepp1xbet 로그인^®(leveti1xbet 로그인cetam) is an antiepileptic drug with over two million patient years experience. Kepp1xbet 로그인^®was first approved in 1999 (US) 1xbet 로그인 2000 (EU) as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Since this time it has received several supplemental indications as adjunctive therapy across both partial 1xbet 로그인 generalised seizures types in the US 1xbet 로그인 the EU. In Keppra^®is also approved as monothe1xbet 로그인py in the EU for the treatment of partial onset seizures in adults with epilepsy.

About Cimzia^®

Cimzia^®is the first 1xbet 로그인 only PEGylated anti-TNF (Tumor Necrosis Factor alpha). Cimzia^®has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research 1xbet 로그인 clinical investigation. This cytokine plays a key role in mediating pathological inflammation, 1xbet 로그인 excess TNF-alpha production has been directly implicated in a wide variety of diseases. UCB is developing Cimzia^®in Crohn's Disease, RA 1xbet 로그인 other autoimmune disease indications. For additional information, please refer to the Cimzia^®website http://www.cimzia.com

About Pletaal^®

Pletaal^®/Pletal^®(Cilostazole) is an antiplatelet agent that exhibits antiplatelet 1xbet 로그인 vasodilatory effects 1xbet 로그인 improves endothelial cells by selectively inhibiting intracellular PDE3 (cGMP-inhibited phosphodiesterase) activity. The agent improves arterial circulation disorders through the antithrombotic effects from the antiplatelet aggregation, the increase in the cerebral blood flow 1xbet 로그인 the blood flow in the lower extremities from the vasodilatory action, 1xbet 로그인 also through the endothelial cell improvement. The drug therefore improves the subjective symptoms of chronic arterial obstruction 1xbet 로그인 prevents recurrence of cerebral infarction.

Forward look1xbet 로그인g statement

This press release contains forward-looking statements based on current plans, estimates 1xbet 로그인 beliefs of management. Such statements are subject to risks 1xbet 로그인 uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business 1xbet 로그인 competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations 1xbet 로그인 hiring 1xbet 로그인 retention of its employees.